CJC/IPA BLEND
Bundle & Save
| Quantity | Discount |
|---|---|
| 1 - 3 | 0% |
| 4 - 5 | 5% |
| 6 - 7 | 8% |
| 8 + | 10% |
| Quantity | Discount |
|---|---|
| 1 - 3 | 0% |
| 4 - 5 | 5% |
| 6 - 7 | 8% |
| 8 + | 10% |
Description
CJC-1295 No DAC / Ipamorelin is a dual-peptide research blend designed for laboratory investigation of growth hormone axis pathway models. CJC-1295 No DAC is studied as a GHRH analog model, while Ipamorelin is studied as a ghrelin receptor-associated growth hormone secretagogue model. Together, this blend supports preclinical research into pituitary signaling, GH-axis interaction, IGF-1-associated response, and endocrine pathway modeling.
This compound is intended strictly for in vitro and preclinical laboratory research.
Specifications
Product Classification: Research-Use-Only (RUO)
Total Content: 5 mg CJC-1295 No DAC and 5 mg Ipamorelin lyophilized powder per vial
Compound: CJC-1295 No DAC and Ipamorelin peptide blend
Form: Sterile lyophilized peptide blend
Purity: ≥99%
Storage: Store at −20 °C, protected from light
Packaging: Glass vial in protective sleeve
Applications
Intended for preclinical laboratory research only, including:
• GHRH receptor pathway research
• Ghrelin receptor-associated signaling studies
• Growth hormone axis pathway models
• Pituitary signaling experiments
• IGF-1-associated pathway analysis
• GH secretagogue blend research
• Comparative endocrine peptide studies
Warning
Not for human or animal use. For research purposes only.
Scientific Report
Abstract
CJC-1295 No DAC and Ipamorelin are peptide research compounds studied for complementary roles in growth hormone axis pathway modeling. CJC-1295 No DAC supports GHRH receptor research, while Ipamorelin supports ghrelin receptor-associated secretagogue pathway research. This blend is designed for laboratory investigation into endocrine signaling, pituitary response, GH-axis pathway interaction, IGF-1-associated signaling, and downstream cellular response models.
Mechanistic Pathway
CJC-1295 No DAC / Ipamorelin is designed around combined GHRH and ghrelin receptor-associated pathway modeling.
CJC-1295 No DAC Pathway
- Supports research into GHRH receptor signaling
• Used in pituitary pathway models
• Studied for GH-axis response research
Effect: Provides a model for GHRH receptor-associated activity.
Ipamorelin Pathway
- Supports research into ghrelin receptor-associated signaling
• Used in growth hormone secretagogue models
• Helps study endocrine pathway response
Effect: Enables research into GHSR-associated secretagogue activity.
Combined GH-Axis Pathway
- Supports research into complementary GH-axis signaling
• Used in peptide blend interaction models
• Helps evaluate downstream IGF-1-associated response
Effect: Provides a dual-pathway model for endocrine signaling research.
Pharmacokinetics / Research Profile
| Compound | Pathway | Research Notes |
| CJC-1295 No DAC / Ipamorelin | GHRH receptor / GHSR / GH axis | Dual-peptide model for endocrine pathway research |
Dosing Models in Research
Used only in controlled in vitro and preclinical research models to study receptor signaling and endocrine pathway response. No human or animal-use instructions are provided.
Preclinical Research Highlights
- Studied as a dual GH-axis research blend
• Used in GHRH and ghrelin receptor-associated pathway models
• Supports pituitary signaling and endocrine response research
• Relevant to IGF-1-associated downstream pathway studies
• Useful for comparative GH secretagogue blend research
Conclusion
CJC-1295 No DAC / Ipamorelin provides a research-use-only model for studying combined GHRH receptor and ghrelin receptor-associated signaling. Its dual-pathway profile supports laboratory research into pituitary response, GH-axis signaling, IGF-1-associated pathways, and endocrine peptide interaction models.
